<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15167">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197184</url>
  </required_header>
  <id_info>
    <org_study_id>208127/132 (EXT Y2)</org_study_id>
    <secondary_id>208127/133 (EXT Y3)</secondary_id>
    <secondary_id>208127/134 (EXT Y4)</secondary_id>
    <secondary_id>208127/137 (EXT Y5)</secondary_id>
    <nct_id>NCT00197184</nct_id>
    <nct_alias>NCT00787449</nct_alias>
  </id_info>
  <brief_title>Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared</brief_title>
  <official_title>Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 Month Schedule and a 0,1,6 Month Schedule, in Healthy Children Aged Between 1-11 Years at the Time of First Vaccine Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the persistence of anti-hepatitis A virus (HAV) and anti-hepatitis B surface
      antigen (HBs) antibodies up to 2, 3, 4 and 5 years after administration of the first dose of
      the study vaccine.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, randomised, self-contained, multicentric, multinational, long-term antibody
      persistence studies. Immune persistence was compared between subjects who received either
      two dose or three doses of GSK Biologicals combined hepatitis A and hepatitis B vaccine. The
      long-term follow-up studies involved taking blood samples at approximately 2, 3, 4 and 5
      years after the primary vaccination of combined hepatitis A and B vaccine to assess antibody
      persistence. No additional subjects will be recruited during the long term follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Anti-hepatitis A (HAV) Antibody Concentrations</measure>
    <time_frame>Year 2 (Month 24), Year 3 (Month 36), Year 4 (Month 48) and Year 5 (Month 60)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentration for anti-HAV antibodies expressed as Milli-International Units per milliliter (mIU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-hepatitis B (HBs) Antibody Concentrations</measure>
    <time_frame>Year 2 (Month 24), Year 3 (Month 36), Year 4 (Month 48) and Year 5 (Month 60)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentration for anti-HBs antibodies expressed as Milli-International Units per milliliter (mIU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HAV Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose.</measure>
    <time_frame>Before and one month after additional vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any subjects becoming seronegative for anti-HAV antibodies (i.e. titres &lt; 15 mIU/ml) at any long term time point, were to receive an additional vaccine dose administered between 6 to 12 months after Year 5 time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HBs Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose.</measure>
    <time_frame>Before and One month after additional vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects losing seroprotective anti-HBs antibody titres (i.e. titres &lt; 10 mIU/ml) at any long term time point, received an Engerix™ challenge dose. The table presents the geometric mean concentrations for anti-HBs antibodies, expressed as Milli-International Units per milliliter (mIU/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs) Determined by the Investigator to Have a Causal Relationship to Primary Vaccination or Due to Lack of Vaccine Efficacy.</measure>
    <time_frame>From last study visit of the primary study up to Year 5 long term follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>A serious adverse event (SAE) is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited Local Symptoms</measure>
    <time_frame>during the 4-day follow-up period after additional vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed include pain, redness and swelling at the vaccine injection site.
Any= regardless of intensity grade; Grade 3 Pain= spontaneously painful</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited General Symptoms.</measure>
    <time_frame>During the 4-day follow-up period after additional vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed include fatigue, fever, gastrointestinal symptoms and headache.
Any= regardless of intensity grade or relationship to vaccination; grade 3= prevented normal activity; Related= considered by the investigator to be causally related to the vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During the 30-day follow-up period after additional vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Any Serious Adverse Events</measure>
    <time_frame>At least one month after additional vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>A serious adverse event (SAE) is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>Twinrix Junior</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twinrix Adult</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Twinrix™ Adult</intervention_name>
    <description>Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.</description>
    <arm_group_label>Twinrix Adult</arm_group_label>
    <other_name>Combined hepatitis A and B vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Twinrix™ Junior</intervention_name>
    <description>Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.</description>
    <arm_group_label>Twinrix Junior</arm_group_label>
    <other_name>Combined hepatitis A and B vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in primary study

          -  Written informed consent obtained before each long term follow up visit.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08042</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blanes (Girona)</city>
        <zip>17300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cerdanyola del Vallés / Barcelona</city>
        <zip>08290</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Marshall H, Nolan T, Díez Domingo J, Rombo L, Sokal EM, Marès J, Casanovas JM, Kuriyakose S, Leyssen M, Jacquet JM. Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. Vaccine. 2010 Jun 17;28(27):4411-5. doi: 10.1016/j.vaccine.2010.04.040. Epub 2010 Apr 29.</citation>
    <PMID>20434544</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>October 2, 2014</lastchanged_date>
  <firstreceived_date>September 15, 2005</firstreceived_date>
  <firstreceived_results_date>February 20, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combined hepatitis A and B vaccine</keyword>
  <keyword>Twinrix™</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Twinrix Adult</title>
          <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
        </group>
        <group group_id="P2">
          <title>Twinrix Junior</title>
          <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Twinrix Adult</title>
          <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
        </group>
        <group group_id="B2">
          <title>Twinrix Junior</title>
          <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="139"/>
                <measurement group_id="B2" value="137"/>
                <measurement group_id="B3" value="276"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11.6" spread="2.97"/>
                <measurement group_id="B2" value="11.2" spread="3.11"/>
                <measurement group_id="B3" value="11.4" spread="3.04"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="59"/>
                <measurement group_id="B2" value="64"/>
                <measurement group_id="B3" value="123"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="80"/>
                <measurement group_id="B2" value="73"/>
                <measurement group_id="B3" value="153"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-hepatitis A (HAV) Antibody Concentrations</title>
        <description>Geometric mean concentration for anti-HAV antibodies expressed as Milli-International Units per milliliter (mIU/mL)</description>
        <time_frame>Year 2 (Month 24), Year 3 (Month 36), Year 4 (Month 48) and Year 5 (Month 60)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Long Term According to Protocol cohort for analysis of immunogenicity (LT ATP immunogenicity cohort) which included all subjects that complied with the protocol and for whom data concerning immunogenicity endpoint measures were available for the particular time point measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Twinrix Adult</title>
            <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
          </group>
          <group group_id="O2">
            <title>Twinrix Junior</title>
            <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="129"/>
                  <measurement group_id="O2" value="119"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-hepatitis A (HAV) Antibody Concentrations</title>
            <description>Geometric mean concentration for anti-HAV antibodies expressed as Milli-International Units per milliliter (mIU/mL)</description>
            <units>mIU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>At year 2 (n=107; 94)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1122.2" lower_limit="937.7" upper_limit="1343.0"/>
                  <measurement group_id="O2" value="1377.8" lower_limit="1114.0" upper_limit="1704.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At year 3 (n=129; 119)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="998.6" lower_limit="845.8" upper_limit="1178.9"/>
                  <measurement group_id="O2" value="1347.1" lower_limit="1145.1" upper_limit="1584.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At year 4 (n=115; 105)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="737.5" lower_limit="623.6" upper_limit="872.3"/>
                  <measurement group_id="O2" value="915.9" lower_limit="774.0" upper_limit="1084.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At year 5 (n=103; 101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="576.8" lower_limit="473.6" upper_limit="702.5"/>
                  <measurement group_id="O2" value="698.4" lower_limit="585.1" upper_limit="833.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-hepatitis B (HBs) Antibody Concentrations</title>
        <description>Geometric mean concentration for anti-HBs antibodies expressed as Milli-International Units per milliliter (mIU/mL).</description>
        <time_frame>Year 2 (Month 24), Year 3 (Month 36), Year 4 (Month 48) and Year 5 (Month 60)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Long Term According to Protocol cohort for analysis of immunogenicity (LT ATP immunogenicity cohort) which included all subjects that complied with the protocol and for whom data concerning immunogenicity endpoint measures were available for the particular time point measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Twinrix Adult</title>
            <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
          </group>
          <group group_id="O2">
            <title>Twinrix Junior</title>
            <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="129"/>
                  <measurement group_id="O2" value="119"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-hepatitis B (HBs) Antibody Concentrations</title>
            <description>Geometric mean concentration for anti-HBs antibodies expressed as Milli-International Units per milliliter (mIU/mL).</description>
            <units>mIU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>At year 2 (n=107; 94)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="479.9" lower_limit="356.6" upper_limit="646.0"/>
                  <measurement group_id="O2" value="830.6" lower_limit="609.5" upper_limit="1131.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At year 3 (n=129; 119)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="325.1" lower_limit="244.7" upper_limit="431.8"/>
                  <measurement group_id="O2" value="695.1" lower_limit="516.5" upper_limit="935.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At year 4 (n=115; 105)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="270.2" lower_limit="201.0" upper_limit="363.3"/>
                  <measurement group_id="O2" value="519.7" lower_limit="378.5" upper_limit="713.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At year 5 (n=102; 100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="150.2" lower_limit="110.5" upper_limit="204.3"/>
                  <measurement group_id="O2" value="283.7" lower_limit="208.6" upper_limit="386.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HAV Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose.</title>
        <description>Any subjects becoming seronegative for anti-HAV antibodies (i.e. titres &lt; 15 mIU/ml) at any long term time point, were to receive an additional vaccine dose administered between 6 to 12 months after Year 5 time point.</description>
        <time_frame>Before and one month after additional vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>None of the subjects became seronegative for anti-HAV antibodies during the Year 2 to Year 5 long term follow-up. Hence none of the subjects received an additional Havrix dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Twinrix Adult</title>
            <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
          </group>
          <group group_id="O2">
            <title>Twinrix Junior</title>
            <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-HAV Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose.</title>
            <description>Any subjects becoming seronegative for anti-HAV antibodies (i.e. titres &lt; 15 mIU/ml) at any long term time point, were to receive an additional vaccine dose administered between 6 to 12 months after Year 5 time point.</description>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HBs Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose.</title>
        <description>Subjects losing seroprotective anti-HBs antibody titres (i.e. titres &lt; 10 mIU/ml) at any long term time point, received an Engerix™ challenge dose. The table presents the geometric mean concentrations for anti-HBs antibodies, expressed as Milli-International Units per milliliter (mIU/mL).</description>
        <time_frame>Before and One month after additional vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total vaccinated cohort for the challenge dose, including all subjects who received an additional vaccine dose between 6 to 12 months after year 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Twinrix Adult</title>
            <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
          </group>
          <group group_id="O2">
            <title>Twinrix Junior</title>
            <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-HBs Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose.</title>
            <description>Subjects losing seroprotective anti-HBs antibody titres (i.e. titres &lt; 10 mIU/ml) at any long term time point, received an Engerix™ challenge dose. The table presents the geometric mean concentrations for anti-HBs antibodies, expressed as Milli-International Units per milliliter (mIU/mL).</description>
            <units>mIU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Before vaccination (n= 6; 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.9" lower_limit="2.1" upper_limit="11.1"/>
                  <measurement group_id="O2" value="2.4" lower_limit="0.9" upper_limit="6.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post vaccination (n= 11; 5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="521.3" lower_limit="158.2" upper_limit="1718.1"/>
                  <measurement group_id="O2" value="509.7" lower_limit="173.5" upper_limit="1497.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs) Determined by the Investigator to Have a Causal Relationship to Primary Vaccination or Due to Lack of Vaccine Efficacy.</title>
        <description>A serious adverse event (SAE) is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>From last study visit of the primary study up to Year 5 long term follow-up</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Long term Total vaccinated cohort wich included all subjects who returned at a specified follow-up study</population>
        <group_list>
          <group group_id="O1">
            <title>Twinrix Adult</title>
            <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
          </group>
          <group group_id="O2">
            <title>Twinrix Junior</title>
            <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="139"/>
                  <measurement group_id="O2" value="137"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events (SAEs) Determined by the Investigator to Have a Causal Relationship to Primary Vaccination or Due to Lack of Vaccine Efficacy.</title>
            <description>A serious adverse event (SAE) is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling at the vaccine injection site.
Any= regardless of intensity grade; Grade 3 Pain= spontaneously painful</description>
        <time_frame>during the 4-day follow-up period after additional vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total vaccinated cohort for the challenge dose, including all subjects who received an additional vaccine dose between 6 to 12 months after year 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Twinrix Adult</title>
            <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
          </group>
          <group group_id="O2">
            <title>Twinrix Junior</title>
            <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited Local Symptoms</title>
            <description>Solicited local symptoms assessed include pain, redness and swelling at the vaccine injection site.
Any= regardless of intensity grade; Grade 3 Pain= spontaneously painful</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain, any</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain, grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness, any</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness, &gt;20mm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling, any</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling, &gt;20mm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited General Symptoms.</title>
        <description>Solicited general symptoms assessed include fatigue, fever, gastrointestinal symptoms and headache.
Any= regardless of intensity grade or relationship to vaccination; grade 3= prevented normal activity; Related= considered by the investigator to be causally related to the vaccination</description>
        <time_frame>During the 4-day follow-up period after additional vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total vaccinated cohort for the challenge dose, including all subjects who received an additional vaccine dose between 6 to 12 months after year 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Twinrix Adult</title>
            <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
          </group>
          <group group_id="O2">
            <title>Twinrix Junior</title>
            <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited General Symptoms.</title>
            <description>Solicited general symptoms assessed include fatigue, fever, gastrointestinal symptoms and headache.
Any= regardless of intensity grade or relationship to vaccination; grade 3= prevented normal activity; Related= considered by the investigator to be causally related to the vaccination</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Fatigue, any</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue, grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue, related</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (axillary), ≥37°C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (axillary), &gt;39.5°C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (axillary), related</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal, any</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal, grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal, related</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache, any</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache, grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache, related</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Unsolicited Adverse Events (AEs).</title>
        <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>During the 30-day follow-up period after additional vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total vaccinated cohort for the challenge dose, including all subjects who received an additional vaccine dose between 6 to 12 months after year 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Twinrix Adult</title>
            <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
          </group>
          <group group_id="O2">
            <title>Twinrix Junior</title>
            <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Unsolicited Adverse Events (AEs).</title>
            <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Any Serious Adverse Events</title>
        <description>A serious adverse event (SAE) is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>At least one month after additional vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total vaccinated cohort for the challenge dose, including all subjects who received an additional vaccine dose between 6 to 12 months after year 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Twinrix Adult</title>
            <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
          </group>
          <group group_id="O2">
            <title>Twinrix Junior</title>
            <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Any Serious Adverse Events</title>
            <description>A serious adverse event (SAE) is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symtoms: During the 4-day (Day 0-3) follow-up period after the additional vaccination. Unsolicited AEs: During the 31-day (Day 0-30) period after the additional vaccination; SAEs: During the entire study period</time_frame>
      <desc>Solicited and unsolicited symptoms were collected on the Total vaccinated cohort for the challenge dose for subjects who received the additional vaccine dose after the Year 5; SAEs were collected on the Long term Total vaccinated cohort throughout the study period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Twinrix Adult</title>
          <description>Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).</description>
        </group>
        <group group_id="E2">
          <title>Twinrix Junior</title>
          <description>Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
